Skip to main content
. 2022 Aug 2;12:816198. doi: 10.3389/fonc.2022.816198

Figure 2.

Figure 2

Treatment response. The CR, PR, SD, and PD rates in HCC patients receiving camrelizumab plus TACE (A); The ORR and DCR rates in HCC patients receiving camrelizumab plus TACE (B). HCC, hepatocellular carcinoma; TACE, transarterial chemoembolization; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; ORR, objective response rate; DCR, disease control rate.